Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Trump picks ex-N. Korea policy official as his principal deputy national security adviser

    Trump picks ex-N. Korea policy official as his principal deputy national security adviser
  2. 2

    S. Korea not to attend Sado mine memorial: foreign ministry

    S. Korea not to attend Sado mine memorial: foreign ministry
  3. 3

    Toxins at 622 times legal limit found in kids' clothes from Chinese platforms

    Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
  4. 4

    Wealthy parents ditch Korean passports to get kids into international school

    Wealthy parents ditch Korean passports to get kids into international school
  5. 5

    [Weekender] Korea's traditional sauce culture gains global recognition

    [Weekender] Korea's traditional sauce culture gains global recognition
  1. 6

    BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'

    BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
  2. 7

    First snow to fall in Seoul on Wednesday

    First snow to fall in Seoul on Wednesday
  3. 8

    Korea to hold own memorial for forced labor victims, boycotting Japan’s

    Korea to hold own memorial for forced labor victims, boycotting Japan’s
  4. 9

    Gyeongju blends old with new

    Gyeongju blends old with new
  5. 10

    Over 80,000 malicious calls made to Seoul call center since 2020

    Over 80,000 malicious calls made to Seoul call center since 2020
피터빈트

SK Chemicals submits Alzheimer’s medication to U.S. FDA

By 손지영

Published : April 3, 2016 - 18:12

    • Link copied

SK Chemicals, a pharmaceutical affiliate of South Korean conglomerate SK Group, on Sunday said it has submitted its patch-type Alzheimer’s drug SID710 to the U.S. Food and Drug Administration for approval.

SID710 is a generic drug referencing Novartis’ Exelon Patch (rivastigmine), a transdermal medication to treat dementia symptoms associated with Alzheimer’s disease.

SK Chemicals` patch-type Alzheimer`s medication S170 (SK Chemicals) SK Chemicals` patch-type Alzheimer`s medication S170 (SK Chemicals)

The Korean drug maker expects the FDA to grant approval in 2018. “We expect the drug to pass through all the review procedures without trouble,” a SK Chemicals spokesperson told The Korea Herald.

SK’s drug was already approved in the European Union in 2013. It currently sells the drug in 13 states in the region, including the U.K., France, Germany and Spain. SID710 takes up around 50 percent of the region’s Exelon Patch generics market, according to the firm.

If approved in the U.S., SID710 will take on the country’s transdermal Alzheimer’s medication market, which generated sales of around $618 million in 2015, according to market analyst IMS Health.

By Sohn Ji-young (jys@heraldcorp.com)

More from Headlines